Pulmonx (LUNG) Projected to Post Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 7th. Analysts expect Pulmonx to post earnings of ($0.37) per share and revenue of $22.03 million for the quarter. Pulmonx has set its FY 2025 guidance at EPS.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.12. The business had revenue of $23.77 million during the quarter, compared to analyst estimates of $22.29 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pulmonx Trading Up 1.5 %

Pulmonx stock opened at $5.27 on Wednesday. The firm has a 50 day moving average of $6.71 and a 200 day moving average of $6.58. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $212.10 million, a price-to-earnings ratio of -3.66 and a beta of 0.61. Pulmonx has a 12-month low of $4.15 and a 12-month high of $10.01.

Insider Activity

In other news, insider Geoffrey Beran Rose sold 5,779 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.13, for a total value of $41,204.27. Following the sale, the insider now directly owns 285,278 shares in the company, valued at approximately $2,034,032.14. This trade represents a 1.99 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven S. Williamson sold 27,689 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $7.14, for a total transaction of $197,699.46. Following the completion of the sale, the chief executive officer now owns 194,342 shares of the company’s stock, valued at approximately $1,387,601.88. This trade represents a 12.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 145,660 shares of company stock valued at $1,128,484. Corporate insiders own 6.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on LUNG. D. Boral Capital assumed coverage on shares of Pulmonx in a report on Monday, March 10th. They issued a “buy” rating and a $17.00 target price for the company. Morgan Stanley started coverage on shares of Pulmonx in a report on Monday, March 10th. They issued an “equal weight” rating for the company. Jefferies Financial Group started coverage on Pulmonx in a research note on Monday, March 10th. They set a “buy” rating on the stock. Finally, Citigroup started coverage on shares of Pulmonx in a research report on Monday, March 10th. They set a “buy” rating on the stock. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Pulmonx currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.75.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.